Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120105452 | 12010545 | 2 | F | 20160711 | 20160205 | 20160917 | PER | US-ASTRAZENECA-2016SE09025 | ASTRAZENECA | 0.00 | F | Y | 68.00000 | KG | 20160917 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 120105452 | 12010545 | 1 | PS | BYDUREON | EXENATIDE | 1 | Subcutaneous | U | U | FL0096 | 22200 | 2 | MG | /wk | |||||
| 120105452 | 12010545 | 2 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | TWO TIMES A DAY | N | U | 0 | SOLUTION FOR INJECTION IN PRE-FILLED PEN | |||||||
| 120105452 | 12010545 | 3 | C | PRILOSEC OTC | OMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | MODIFIED-RELEASE TABLET | ||||||||||
| 120105452 | 12010545 | 4 | C | PRILOSEC | OMEPRAZOLE MAGNESIUM | 1 | Oral | 0 | |||||||||||
| 120105452 | 12010545 | 5 | C | SENOKOT-S | DOCUSATE SODIUMSENNOSIDES | 1 | Unknown | 0 | |||||||||||
| 120105452 | 12010545 | 6 | C | SUDAFED | PSEUDOEPHEDRINE HYDROCHLORIDE | 1 | Unknown | 0 | |||||||||||
| 120105452 | 12010545 | 7 | C | DONNATAL | ATROPINE SULFATEHYOSCYAMINE SULFATEPHENOBARBITALSCOPOLAMINE HYDROBROMIDE | 1 | Unknown | 0 | |||||||||||
| 120105452 | 12010545 | 8 | C | WELLBUTRIN | BUPROPION HYDROCHLORIDE | 1 | Oral | 0 | 150 | MG | QD | ||||||||
| 120105452 | 12010545 | 9 | C | ZYRTEC | CETIRIZINE HYDROCHLORIDE | 1 | Unknown | 0 | |||||||||||
| 120105452 | 12010545 | 10 | C | VALSARTAN. | VALSARTAN | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 120105452 | 12010545 | 11 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | Oral | 0 | 125 | MG | QD | ||||||||
| 120105452 | 12010545 | 12 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 500 | MG | Q8H | ||||||||
| 120105452 | 12010545 | 13 | C | LANTUS | INSULIN GLARGINE | 1 | Subcutaneous | 0 | 30 | IU | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 120105452 | 12010545 | 1 | Type 2 diabetes mellitus |
| 120105452 | 12010545 | 2 | Type 2 diabetes mellitus |
| 120105452 | 12010545 | 10 | Hypertension |
| 120105452 | 12010545 | 11 | Thyroid disorder |
| 120105452 | 12010545 | 12 | Diabetes mellitus |
| 120105452 | 12010545 | 13 | Diabetes mellitus |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 120105452 | 12010545 | Circumstance or information capable of leading to medication error | |
| 120105452 | 12010545 | Injection site mass | |
| 120105452 | 12010545 | Needle issue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 120105452 | 12010545 | 1 | 201511 | 0 | ||
| 120105452 | 12010545 | 2 | 201510 | 0 | ||
| 120105452 | 12010545 | 8 | 2006 | 0 | ||
| 120105452 | 12010545 | 10 | 1991 | 0 | ||
| 120105452 | 12010545 | 11 | 1991 | 0 | ||
| 120105452 | 12010545 | 12 | 1991 | 0 | ||
| 120105452 | 12010545 | 13 | 2001 | 0 |